Literature DB >> 8321121

Vascular clearance of Borrelia burgdorferi in rats.

J L Galbe1, E Guy, J M Zapatero, E I Peerschke, J L Benach.   

Abstract

Radiolabeled Borrelia burgdorferi, the etiologic agent of Lyme disease, injected intravenously into rats are cleared from the vasculature within 1 h of injection. One low passage isolate showed trafficking between the circulation and possibly the vessel walls for the first 2 h after injection. All strains used were resistant to the effects of normal and heat-inactivated rat serum. During the first 2 h after injection, B. burgdorferi can be visualized in, and recovered from, the platelet-rich plasma. B. burgdorferi can adhere to both human and rat platelets in in vitro assays, but an in vivo association with these cells was not apparent. Similarly, none of the strains of B. burgdorferi used induced platelet aggregation. Removal from the circulation into the organs was measured in perfused rats by polymerase chain reaction and autoradiography and in non-perfused rats by organ cultures. These organisms invade organs (heart, kidneys, bladder, liver, spleen, brain) within 1-6 h after injection. Invasion of organs occurred in an apparent random manner; a large amount of radiolabel but no live organisms was excreted in the urine during the first 24 h, suggesting degradation of the inoculum.

Entities:  

Mesh:

Year:  1993        PMID: 8321121     DOI: 10.1006/mpat.1993.1019

Source DB:  PubMed          Journal:  Microb Pathog        ISSN: 0882-4010            Impact factor:   3.738


  16 in total

1.  Fibronectin binding protein BBK32 of the Lyme disease spirochete promotes bacterial attachment to glycosaminoglycans.

Authors:  Joshua R Fischer; Kimberly T LeBlanc; John M Leong
Journal:  Infect Immun       Date:  2006-01       Impact factor: 3.441

2.  Platelet-activating-factor-mediated pathogenesis in Lyme disease.

Authors:  E Isogai; K Kimura; N Fujii; T Nishikawa; N Ishii; D Postic; G Baranton; H Isogai
Journal:  Infect Immun       Date:  1996-03       Impact factor: 3.441

3.  Borrelia burgdorferi induces secretion of pro-urokinase-type plasminogen activator by human monocytes.

Authors:  H Fuchs; M M Simon; R Wallich; M Bechtel; M D Kramer
Journal:  Infect Immun       Date:  1996-10       Impact factor: 3.441

4.  Different classes of proteoglycans contribute to the attachment of Borrelia burgdorferi to cultured endothelial and brain cells.

Authors:  J M Leong; H Wang; L Magoun; J A Field; P E Morrissey; D Robbins; J B Tatro; J Coburn; N Parveen
Journal:  Infect Immun       Date:  1998-03       Impact factor: 3.441

5.  Integrins alpha(v)beta3 and alpha5beta1 mediate attachment of lyme disease spirochetes to human cells.

Authors:  J Coburn; L Magoun; S C Bodary; J M Leong
Journal:  Infect Immun       Date:  1998-05       Impact factor: 3.441

6.  Allelic variation of the Lyme disease spirochete adhesin DbpA influences spirochetal binding to decorin, dermatan sulfate, and mammalian cells.

Authors:  Vivian M Benoit; Joshua R Fischer; Yi-Pin Lin; Nikhat Parveen; John M Leong
Journal:  Infect Immun       Date:  2011-06-27       Impact factor: 3.441

7.  Delineation of Borrelia burgdorferi p66 sequences required for integrin alpha(IIb)beta(3) recognition.

Authors:  G Defoe; J Coburn
Journal:  Infect Immun       Date:  2001-05       Impact factor: 3.441

8.  Strain variation in glycosaminoglycan recognition influences cell-type-specific binding by lyme disease spirochetes.

Authors:  N Parveen; D Robbins; J M Leong
Journal:  Infect Immun       Date:  1999-04       Impact factor: 3.441

9.  The plasminogen activation system enhances brain and heart invasion in murine relapsing fever borreliosis.

Authors:  J A Gebbia; J C Monco; J L Degen; T H Bugge; J L Benach
Journal:  J Clin Invest       Date:  1999-01       Impact factor: 14.808

10.  Decorin-binding proteins A and B confer distinct mammalian cell type-specific attachment by Borrelia burgdorferi, the Lyme disease spirochete.

Authors:  Joshua R Fischer; Nikhat Parveen; Loranne Magoun; John M Leong
Journal:  Proc Natl Acad Sci U S A       Date:  2003-05-28       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.